New York & Co. Inc (NWY) Drops 7.77% on February 15

Equities Staff |

New York & Co. Inc (NWY) was one of the Russell 2000's biggest losers for Monday February 15 as the stock slid 7.77% to $1.90, a loss of $-0.16 per share. Starting at an opening price of $2.09 a share, the stock traded between $1.89 and $2.15 over the course of the trading day. Volume was 16,418 shares over 113 trades, against an average daily volume of 67,964 shares and a total float of 64.53 million.

The losses send New York & Co. Inc down to a market cap of $122.6 million. In the last year, New York & Co. Inc has traded between $3.11 and $1.89, and its 50-day SMA is currently $2.28 and 200-day SMA is $2.43.

New York & Company Inc together with its subsidiaries is a specialty retailer of women's fashion apparel & accessories, & the modern wear-to-work destination for women. It provides fitting pants & NY Style that is feminine, polished, on-trend & versatile.

New York & Co. Inc is based out of New York, NY and has some 6,400 employees. Its CEO is .

For a complete fundamental analysis analysis of New York & Co. Inc, check out’s Stock Valuation Analysis report for NWY. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…